Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, Antihemophilic Factor (recombinant)

By Pharmaceutical Processing | August 7, 2009

Bayer HealthCarePharmaceuticals has announced that the FDA hasapproved a 3000 IU (international unit) vial size of Kogenate FS,antihemophilic factor (recombinant). The new vial size offers greaterconvenience for patients with hemophilia A who require a higher dose.The 3000 IU vial may eliminate the need for combining smaller vials andmay allow some patients to achieve more precise dosing. It is available in aconventional vial-to-vial reconstitution system and in Kogenate FS Grab & Gopackaging with BIO-SET , a compact and complete reconstitution system. Grab &Go includes the Terumo SURFLO Infusion Set with filter and other materialsnecessary for safe reconstitution and fast recombinant factor VIII treatmentin a small, tamper-evident box with anticounterfeiting features. “The availability of Kogenate FS in a 3000 IU vial demonstrates Bayer’scommitment to adolescent and adult patients, who are more likely to have aneed for higher doses and who will appreciate the greater convenience of thelarger vial,” said Joni Osip, RN, MS, Hemophilia Nurse Coordinator, Center forBleeding and Clotting Disorders at the University of Minnesota Medical Center,Fairview, in Minneapolis. The Kogenate FS line of products now includes the following vial sizes:250, 500, 1000, 2000 and 3000 IU. Kogenate FS has one of the smallest diluentvolumes available. The 250, 500 and 1000 IU vial sizes are provided with 2.5mL of diluent; the 2000 and 3000 IU vial sizes are reconstituted with 5 mL ofdiluent. The 3000 IU vial size is now part of the Kogenate FS Free TrialProgram, which is open to people with hemophilia A who meet programeligibility criteria. “The 3000 IU vial size is being offered in response to customer needs andis part of Bayer’s ongoing efforts to introduce enhancements for the benefitof the people who are treated with Kogenate FS,” said Paul Bedard, VicePresident and General Manager, Hematology, Bayer HealthCare Pharmaceuticals.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE